Because improved vascular functionality is the aim of tumor vessel normalization approaches, DKK1 and DKK2 effects on angiogenesis and vessel functionality that regulates tumor hypoxia might be purposefully exploited in developing novel cancer treatments. This evidence concerns the gene DKK2 and cancer.